First oral treatment for hormone-sensitive prostate cancer recommended by NICE
Natalia Elliot | August 15, 2024 | News story | Research and Development | Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer
Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral androgen deprivation therapy (ADT) treatment for hormone-sensitive prostate cancer. Prostate cancer is the most common cancer in men across the UK.
Orgovyx (relugolix), an oral ADT treatment for hormone-sensitive prostate cancer, will offer patients a first-time choice between an oral or injectable ADT. It is applicable to patients with advanced hormone-sensitive prostate cancer who are also receiving radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer.
Consultant clinical oncologist at the Bristol Cancer Institute, UK, and Professor Amit Bahl commented: “Through the recent pandemic, we have seen a growing need for flexibility in treatment administration.”
Prostate cancer cells usually require androgen (male) hormones, such as testosterone, to grow. Stopping the release of testosterone from the testicles in prostate cancer through the use of ADTs is called medical castration and is a cornerstone of the medical treatment of prostate cancer. Injectable ADTs are currently the standard agents for achieving androgen deprivation for prostate cancer.
Steve Allen, retired doctor, prostate cancer patient representative at Tackle Prostate Cancer and patient, also commented: “Today’s approval marks an important milestone for the prostate cancer community. Living with prostate cancer is a daily challenge. From my own experience as both a patient and medical professional, I understand the burden that prostate cancer can place on every facet of life.”
Related Content
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication …
Biocon Biologics gains EU approval for bone health therapies
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab …
Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology
Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland …
